ID   AVR2B_HUMAN             Reviewed;         512 AA.
AC   Q13705; Q4VAV0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-MAY-2006, sequence version 3.
DT   02-NOV-2010, entry version 114.
DE   RecName: Full=Activin receptor type-2B;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor type IIB;
DE            Short=ACTR-IIB;
DE   Flags: Precursor;
GN   Name=ACVR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=94214127; PubMed=8161782;
RA   Hilden K., Tuuri T., Eramaa M., Ritvos O.;
RT   "Expression of type II activin receptor genes during differentiation
RT   of human K562 cells and cDNA cloning of the human type IIB activin
RT   receptor.";
RL   Blood 83:2163-2170(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASP-459.
RX   MEDLINE=98284539; PubMed=9621519; DOI=10.1007/s100380050054;
RA   Ishikawa S., Kai M., Murata Y., Tamari M., Daigo Y., Murano T.,
RA   Ogawa M., Nakamura Y.;
RT   "Genomic organization and mapping of the human activin receptor type
RT   IIB (hActR-IIB) gene.";
RL   J. Hum. Genet. 43:132-134(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS
RP   HTX4 HIS-40 AND ILE-494.
RX   MEDLINE=99113885; PubMed=9916847;
RX   DOI=10.1002/(SICI)1096-8628(19990101)82:1<70::AID-AJMG14>3.0.CO;2-Y;
RA   Kosaki R., Gebbia M., Kosaki K., Lewin M., Bowers P., Towbin J.A.,
RA   Casey B.;
RT   "Left-right axis malformations associated with mutations in ACVR2B,
RT   the gene for human activin receptor type IIB.";
RL   Am. J. Med. Genet. 82:70-76(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-176.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for activin A, activin B and
CC       inhibin A.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=ActR-IIB2;
CC         IsoId=Q13705-1; Sequence=Displayed;
CC       Name=ActR-IIB1;
CC         IsoId=Q13705-2; Sequence=Not described;
CC         Note=Produced from the insertion in the transcript of 82 base
CC         pairs, leading to frameshift and protein truncation. May be not
CC         functional;
CC   -!- DISEASE: Defects in ACVR2B are the cause of visceral heterotaxy
CC       autosomal type 4 (HTX4) [MIM:602730]. A form of visceral
CC       heterotaxy, a complex disorder due to disruption of the normal
CC       left-right asymmetry of the thoracoabdominal organs. It results in
CC       an abnormal arrangement of visceral organs, and a wide variety of
CC       congenital defects. Clinical features of visceral heterotaxy type
CC       4 include dextrocardia, right aortic arch and a right-sided
CC       spleen, anomalies of the inferior and the superior vena cava,
CC       atrial ventricular canal defect with dextro-transposed great
CC       arteries, pulmonary stenosis, polysplenia and midline liver.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ACVR2B";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77533; CAA54671.1; -; mRNA.
DR   EMBL; AB008681; BAA24180.2; -; Genomic_DNA.
DR   EMBL; AF060202; AAC64515.1; -; Genomic_DNA.
DR   EMBL; AF060199; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; AF060200; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; AF060201; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; BC096243; AAH96243.1; -; mRNA.
DR   EMBL; BC096244; AAH96244.1; -; mRNA.
DR   EMBL; BC099642; AAH99642.1; -; mRNA.
DR   IPI; IPI00437565; -.
DR   PIR; I37134; I37134.
DR   RefSeq; NP_001097.2; -.
DR   UniGene; Hs.174273; -.
DR   PDB; 2H62; X-ray; 1.85 A; D=19-116.
DR   PDB; 2QLU; X-ray; 2.00 A; A=190-487.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2QLU; -.
DR   ProteinModelPortal; Q13705; -.
DR   SMR; Q13705; 24-117.
DR   STRING; Q13705; -.
DR   PRIDE; Q13705; -.
DR   Ensembl; ENST00000352511; ENSP00000340361; ENSG00000114739.
DR   GeneID; 93; -.
DR   KEGG; hsa:93; -.
DR   UCSC; uc003cif.1; human.
DR   CTD; 93; -.
DR   GeneCards; GC03P038470; -.
DR   H-InvDB; HIX0030708; -.
DR   HGNC; HGNC:174; ACVR2B.
DR   HPA; CAB025115; -.
DR   MIM; 602730; gene+phenotype.
DR   Orphanet; 157769; Situs ambiguus.
DR   PharmGKB; PA24495; -.
DR   eggNOG; prNOG16481; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; Q13705; -.
DR   OMA; NLETELW; -.
DR   OrthoDB; EOG99S8RM; -.
DR   PhylomeDB; Q13705; -.
DR   BRENDA; 2.7.11.30; 247.
DR   Reactome; REACT_12034; Signaling by BMP.
DR   NextBio; 351; -.
DR   ArrayExpress; Q13705; -.
DR   Bgee; Q13705; -.
DR   CleanEx; HS_ACVR2B; -.
DR   Genevestigator; Q13705; -.
DR   GermOnline; ENSG00000114739; Homo sapiens.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0017002; F:activin receptor activity; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:HGNC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0009952; P:anterior/posterior pattern formation; IMP:HGNC.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032927; P:positive regulation of activin receptor sig...; IDA:HGNC.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast different...; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of transcription; IDA:HGNC.
DR   InterPro; IPR000333; Activin_II_recpt.
DR   InterPro; IPR015768; Activin_II_recpt_C.
DR   InterPro; IPR000472; Activin_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   PANTHER; PTHR23255:SF10; Activin_II_recpt_C; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Heterotaxy; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Polymorphism; Receptor; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     18       Potential.
FT   CHAIN        19    512       Activin receptor type-2B.
FT                                /FTId=PRO_0000024404.
FT   TOPO_DOM     19    137       Extracellular (Potential).
FT   TRANSMEM    138    158       Helical; (Potential).
FT   TOPO_DOM    159    512       Cytoplasmic (Potential).
FT   DOMAIN      190    480       Protein kinase.
FT   NP_BIND     196    204       ATP (By similarity).
FT   ACT_SITE    321    321       Proton acceptor (By similarity).
FT   BINDING     217    217       ATP (By similarity).
FT   CARBOHYD     42     42       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     65     65       N-linked (GlcNAc...) (Potential).
FT   DISULFID     29     59       By similarity.
FT   DISULFID     49     77       By similarity.
FT   DISULFID     84    103       By similarity.
FT   DISULFID     90    102       By similarity.
FT   DISULFID    104    109       By similarity.
FT   VARIANT      40     40       R -> H (in HTX4).
FT                                /FTId=VAR_013281.
FT   VARIANT     176    176       P -> R (in dbSNP:rs35882617).
FT                                /FTId=VAR_041396.
FT   VARIANT     459    459       E -> D (in dbSNP:rs500611).
FT                                /FTId=VAR_050594.
FT   VARIANT     494    494       V -> I (in HTX4).
FT                                /FTId=VAR_013282.
FT   CONFLICT     16     17       CA -> WP (in Ref. 1; CAA54671).
FT   CONFLICT     64     64       R -> A (in Ref. 1 and 2).
FT   CONFLICT    459    459       E -> A (in Ref. 3; AAC64515).
FT   STRAND       27     33
FT   HELIX        36     39
FT   STRAND       43     49
FT   STRAND       57     66
FT   STRAND       69     79
FT   HELIX        82     84
FT   STRAND       88     91
FT   STRAND       98    106
FT   TURN        107    110
FT   STRAND      111    114
FT   STRAND      191    197
FT   STRAND      200    209
FT   STRAND      212    219
FT   HELIX       221    223
FT   HELIX       224    235
FT   STRAND      247    253
FT   TURN        256    258
FT   STRAND      260    266
FT   HELIX       273    279
FT   HELIX       284    302
FT   STRAND      305    308
FT   TURN        309    311
FT   STRAND      312    314
FT   STRAND      316    318
FT   HELIX       324    326
FT   STRAND      327    329
FT   STRAND      335    337
FT   STRAND      344    346
FT   HELIX       362    364
FT   HELIX       367    370
FT   HELIX       378    398
FT   TURN        413    417
FT   HELIX       424    431
FT   HELIX       442    446
FT   HELIX       448    460
FT   HELIX       465    467
FT   HELIX       471    482
SQ   SEQUENCE   512 AA;  57724 MW;  B377FEF92EF74937 CRC64;
     MTAPWVALAL LWGSLCAGSG RGEAETRECI YYNANWELER TNQSGLERCE GEQDKRLHCY
     ASWRNSSGTI ELVKKGCWLD DFNCYDRQEC VATEENPQVY FCCCEGNFCN ERFTHLPEAG
     GPEVTYEPPP TAPTLLTVLA YSLLPIGGLS LIVLLAFWMY RHRKPPYGHV DIHEDPGPPP
     PSPLVGLKPL QLLEIKARGR FGCVWKAQLM NDFVAVKIFP LQDKQSWQSE REIFSTPGMK
     HENLLQFIAA EKRGSNLEVE LWLITAFHDK GSLTDYLKGN IITWNELCHV AETMSRGLSY
     LHEDVPWCRG EGHKPSIAHR DFKSKNVLLK SDLTAVLADF GLAVRFEPGK PPGDTHGQVG
     TRRYMAPEVL EGAINFQRDA FLRIDMYAMG LVLWELVSRC KAADGPVDEY MLPFEEEIGQ
     HPSLEELQEV VVHKKMRPTI KDHWLKHPGL AQLCVTIEEC WDHDAEARLS AGCVEERVSL
     IRRSVNGTTS DCLVSLVTSV TNVDLPPKES SI
//
